Spyre Therapeutics Reconciled Depreciation Over Time
| SYRE Stock | 27.00 0.50 1.82% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Spyre Therapeutics Performance and Spyre Therapeutics Correlation. Spyre |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (37.90) | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Spyre Therapeutics is measured differently than its book value, which is the value of Spyre that is recorded on the company's balance sheet. Investors also form their own opinion of Spyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spyre Therapeutics' market value can be influenced by many factors that don't directly affect Spyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Reconciled Depreciation Analysis
Compare Spyre Therapeutics and related stocks such as Paysafe, Evertz Technologies, and Bridgford Foods Reconciled Depreciation Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PSFE | 234.3 M | 234.3 M | 234.3 M | 234.3 M | 234.3 M | 234.3 M | 234.3 M | 234.3 M | 234.3 M | 279.8 M | 268.2 M | 261.4 M | 266.8 M | 264.8 M | 288.8 M |
| BRID | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.4 M | 3.9 M | 4.2 M | 5.5 M | 6.7 M | 6.7 M | 6.6 M | 7.5 M | 5.8 M |
| STKL | 32.8 M | 32.8 M | 32.8 M | 32.8 M | 32.8 M | 32.8 M | 32.8 M | 32.8 M | 32.8 M | 34 M | 30.3 M | 34.6 M | 37.7 M | 31 M | 36.6 M |
| TSN | 761 M | 761 M | 761 M | 761 M | 761 M | 761 M | 761 M | 943 M | 1.1 B | 1.2 B | 1.2 B | 1.2 B | 1.3 B | 1.5 B | 1.2 B |
| ACI | 1.9 B | 1.9 B | 1.9 B | 1.9 B | 1.9 B | 1.9 B | 1.9 B | 1.9 B | 1.7 B | 2.1 B | 2.1 B | 2.3 B | 2.5 B | 2.4 B | 2.4 B |
Spyre Therapeutics and related stocks such as Paysafe, Evertz Technologies, and Bridgford Foods Reconciled Depreciation description
My Equities
My Current Equities and Potential Positions
Check out Spyre Therapeutics Performance and Spyre Therapeutics Correlation. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Spyre Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.